报价延迟最少15分钟:2026/05/06 18:16 EDT
盘后时段
|
||||
|
90.42 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
90.42
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.20/-5.59
|
|
企业价值
4.91B
|
| 资产负债 |
|
每股账面净值
9.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.04M
|
|
每股收益
0.12
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic. |
